Great Point Partners LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Great Point Partners LLC reported 35 stock positions worth $641.6 million. Its top holding was Neurogene (NGNE) at 8.0% of the portfolio, followed by Alpine Immune Sciences (ALPN, 7.0%) and Urogen Pharma (URGN, 6.1%). Compared with Q4 2023, it opened 10 new positions, sold out of 9, added to 11 and reduced 8. The biggest buy was Neurogene (NGNE, shares +1%) and the biggest sale an exit from Ultragenyx Pharmaceutical (RARE).
- Most Recent 13F
- Q2 2026
- Location
- Greenwich, CT
- CIK
- 0001281446
- Portfolio Value
- $641.6M (Q1 2024)
- SEC Filing
- 0001172661-24-002523 ↗ filed May 15, 2024
Holdings Value
Holdings 35 stocks · $641.6M
| NGNE Neurogene Inc. | 7.97% | 1,004,291 | $51.1M | Add +1.0% |
| ALPN Alpine Immune Sciences Inc. | 6.97% | 1,128,499 | $44.7M | Reduce -69.5% |
| URGN Urogen Pharma Ltd. | 6.13% | 2,620,545 | $39.3M | No change |
| ABVX Abivax SA-ADR | 5.55% | 2,488,483 | $35.6M | Add +60.5% |
| EOLS Evolus Inc. | 5.35% | 2,450,000 | $34.3M | Add +22.5% |
| PLRX Pliant Therapeutics Inc. | 4.30% | 1,851,864 | $27.6M | Add +1.6% |
| APGE Apogee Therapeutics Inc. | 4.14% | 400,000 | $26.6M | No change |
| AEROVATE THERAPEUTICS INC | 4.09% | 887,690 | $26.2M | Reduce -14.5% |
| VRDN Viridian Therapeutics Inc. | 3.64% | 1,335,000 | $23.4M | New |
| ANAB Anaptysbio Inc. | 3.43% | 976,981 | $22.0M | No change |
| ESPR Esperion Therapeutics Inc. | 3.34% | 8,000,000 | $21.4M | New |
| INSM Insmed Inc. | 3.28% | 775,585 | $21.0M | Add +243.3% |
| ACLX Arcellx Inc. | 3.25% | 300,000 | $20.9M | Add +521.6% |
| XENE Xenon Pharmaceuticals Inc. | 3.06% | 456,148 | $19.6M | Reduce -24.0% |
| MIND MEDICINE MINDMED INC | 2.93% | 2,000,000 | $18.8M | New |
| DNTH Dianthus Therapeutics Inc. | 2.92% | 625,000 | $18.8M | New |
| OTLK Outlook Therapeutics Inc. | 2.75% | 1,480,000 | $17.7M | New |
| FOLD Amicus Therapeutics Inc. | 2.75% | 1,495,500 | $17.6M | Add +16.8% |
| OCUL Ocular Therapeutix Inc. | 2.45% | 1,728,723 | $15.7M | Add +147.0% |
| DVAX Dynavax Technologies Corp. | 2.45% | 1,264,920 | $15.7M | New |
| CYTK Cytokinetics Inc. | 2.21% | 202,202 | $14.2M | Reduce -59.6% |
| OPTINOSE INC | 2.00% | 8,786,318 | $12.8M | Reduce -0.6% |
| JSPR Jasper Therapeutics Inc. | 1.86% | 407,550 | $12.0M | New |
| ITCI Intra-Cellular Therapies Inc. | 1.62% | 150,000 | $10.4M | Add +35.6% |
| MRUS Merus NV | 1.57% | 223,288 | $10.1M | Add +1016.4% |
| VTGN Vistagen Therapeutics Inc. | 1.53% | 1,858,735 | $9.8M | No change |
| TERN Terns Pharmaceuticals Inc. | 1.34% | 1,309,975 | $8.6M | No change |
| IMCR Immunocore Holdings PLC-ADR | 1.17% | 115,000 | $7.5M | Reduce -60.8% |
| AUTL Autolus Therapeutics PLC | 1.16% | 1,166,667 | $7.4M | New |
| PBYI Puma Biotechnology Inc. | 1.11% | 1,343,628 | $7.1M | Add +22.9% |
| ZURA Zura Bio Ltd. | 1.10% | 2,757,740 | $7.1M | Reduce -16.3% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.81% | 500,000 | $5.2M | New |
| SYRE Spyre Therapeutics Inc. | 0.74% | 125,000 | $4.7M | No change |
| KYTX Kyverna Therapeutics Inc. | 0.58% | 150,000 | $3.7M | New |
| ARVN Arvinas Inc. | 0.46% | 71,113 | $2.9M | Reduce -69.6% |
Portfolio Sells Q4 2023 → Q1 2024
| RARE Ultragenyx Pharmaceutical Inc. | Sold out | 0.00% | −5.28 |
| ALPN Alpine Immune Sciences Inc. | Reduce -69.5% | 6.97% | −5.06 |
| CYTK Cytokinetics Inc. | Reduce -59.6% | 2.21% | −4.91 |
| RAPT THERAPEUTICS INC | Sold out | 0.00% | −4.66 |
| ALKS Alkermes PLC | Sold out | 0.00% | −4.14 |
| PCVX Vaxcyte Inc. | Sold out | 0.00% | −3.85 |
| TRML Tourmaline Bio Inc. | Sold out | 0.00% | −3.00 |
| IMCR Immunocore Holdings PLC-ADR | Reduce -60.8% | 1.17% | −2.25 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -24.0% | 3.06% | −1.65 |
| KRTX Karuna Therapeutics Inc. | Sold out | 0.00% | −1.63 |
| ZURA Zura Bio Ltd. | Reduce -16.3% | 1.10% | −1.52 |
| SRPT Sarepta Therapeutics Inc. | Sold out | 0.00% | −1.31 |
| ARVN Arvinas Inc. | Reduce -69.6% | 0.46% | −1.18 |
| AXSM Axsome Therapeutics Inc. | Sold out | 0.00% | −0.07 |
| MURA Mural Oncology PLC | Sold out | 0.00% | −0.01 |
| OPTINOSE INC | Reduce -0.6% | 2.00% | +0.06 |
| AEROVATE THERAPEUTICS INC | Reduce -14.5% | 4.09% | +0.09 |
Portfolio Buys Q4 2023 → Q1 2024
| NGNE Neurogene Inc. | Add +1.0% | 7.97% | +4.68 |
| VRDN Viridian Therapeutics Inc. | New | 3.64% | +3.64 |
| ESPR Esperion Therapeutics Inc. | New | 3.34% | +3.34 |
| MIND MEDICINE MINDMED INC | New | 2.93% | +2.93 |
| DNTH Dianthus Therapeutics Inc. | New | 2.92% | +2.92 |
| ACLX Arcellx Inc. | Add +521.6% | 3.25% | +2.80 |
| OTLK Outlook Therapeutics Inc. | New | 2.75% | +2.75 |
| ABVX Abivax SA-ADR | Add +60.5% | 5.55% | +2.72 |
| DVAX Dynavax Technologies Corp. | New | 2.45% | +2.45 |
| INSM Insmed Inc. | Add +243.3% | 3.28% | +2.09 |
| OCUL Ocular Therapeutix Inc. | Add +147.0% | 2.45% | +1.92 |
| JSPR Jasper Therapeutics Inc. | New | 1.86% | +1.86 |
| EOLS Evolus Inc. | Add +22.5% | 5.35% | +1.76 |
| MRUS Merus NV | Add +1016.4% | 1.57% | +1.47 |
| AUTL Autolus Therapeutics PLC | New | 1.16% | +1.16 |
| BBOT Bridgebio Oncology Therapeut | New | 0.81% | +0.81 |
| KYTX Kyverna Therapeutics Inc. | New | 0.58% | +0.58 |
| PBYI Puma Biotechnology Inc. | Add +22.9% | 1.11% | +0.30 |
| ITCI Intra-Cellular Therapies Inc. | Add +35.6% | 1.62% | +0.27 |
| FOLD Amicus Therapeutics Inc. | Add +16.8% | 2.75% | −0.35 |
| PLRX Pliant Therapeutics Inc. | Add +1.6% | 4.30% | −1.33 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 37 | $424.4M | VOR, ABVX, VERA, ZURA, ALMS |
| Q1 2026 | 39 | $408.3M | APGE, VOR, ZURA, AMLX, NKTR |
| Q4 2025 | 29 | $308.4M | APGE, AMLX, ZURA, IRON, RAPT |
| Q3 2025 | 28 | $239.5M | AMLX, RZLT, NKTR, ZURA, SLNO |
| Q2 2025 | 26 | $153.8M | IONS, RZLT, AMLX, LEGN, ABVX |
| Q1 2025 | 31 | $184.0M | CYTK, KALV, EOLS, ABVX, VRDN |
| Q4 2024 | 26 | $212.2M | IONS, CYTK, KALV, VRDN, PLRX |
| Q3 2024 | 29 | $331.4M | NGNE, ABVX, PLRX, EOLS, VRDN |
| Q2 2024 | 33 | $522.0M | URGN, NGNE, ABVX, MRUS, PLRX |
| Q1 2024 | 35 | $641.6M | NGNE, ALPN, URGN, ABVX, EOLS |